The online version of this article (doi:10.1186/s12879-017-2334-8) contains supplementary material, which is available to authorized users.
Increased incidence of cardiovascular diseases (CVD) in both HIV infection and type 2 diabetes (T2D) compared to the general population has been described. Little is known about the combined effect of HIV infection and T2D on inflammation and endothelial function, both of which may contribute to elevated risk of CVD.
Cross-sectional study including 50 HIV-infected persons on combination anti-retroviral therapy (cART), with HIV RNA <200 copies/mL (n = 25 with T2D (HIV + T2D+), n = 25 without T2D (HIV + T2D-)) and 50 uninfected persons (n = 22 with T2D (HIV-T2D+) and n = 28 without T2D (HIV-T2D-)). Groups were matched on age and sex.
High sensitive C-reactive protein (hsCRP) was used to determine inflammation (cut-off 3 mg/L). The marker of endothelial dysfunction asymmetric dimethylarginine (ADMA) was measured using high performance liquid chromatography. Trimethylamine-N-oxide (TMAO), a microbiota-dependent, pro-atherogenic marker was measured using stable isotope dilution LC/MS/MS.
The percentage of HIV + T2D+, HIV + T2D-, HIV-T2D+, and HIV-T2D- with hsCRP above cut-off was 50%, 19%, 47%, and 11%, respectively. HIV + T2D+ had elevated ADMA (0.67 μM (0.63-0.72) compared to HIV + T2D- (0.60 μM (0.57-0.64) p = 0.017), HIV-T2D+ (0.57 μM (0.51-63) p = 0.008), and HIV-T2D- (0.55 μM (0.52-0.58) p < 0.001). No differences in TMAO between groups were found. However, a positive correlation between ADMA and TMAO was found in the total population (rs = 0.32, p = 0.001), which was mainly driven by a close correlation in HIV + T2D+ (rs = 0.63, p = 0.001).
Elevated inflammation and evidence of endothelial dysfunction was found in HIV-infected persons with T2D. The effect on inflammation was mainly driven by T2D, while both HIV infection and T2D may contribute to endothelial dysfunction. Whether gut microbiota is a contributing factor to this remains to be determined.
Additional file 1: Table S3. HIV+T2D+: HIV infected persons with type 2 diabetes, TMAO: Trimethylamine-N-oxide. (PPTX 46 kb)12879_2017_2334_MOESM1_ESM.pptx
Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. Asian J Infect Dis. 2012;205(Suppl 3):S375–82. CrossRef
Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:a:D study). Circulation. 2009;119(6):805–11. CrossRefPubMedPubMedCentral
Dooko CBA, Wit SD, Neuhaus J, Palfreeman A, Pepe R, Pankow JS, Neaton JD, Smart I, Groups ES. Interleukin-6, High Sensitivity C-Reactive Protein, and the Development of Type 2 Diabetes Among HIV-Positive Patients Taking Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2014; 67(5):538–46. CrossRefPubMedCentral
Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, Hernandez RD, Lederman MM, Huang Y, Somsouk M, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Science translational medicine. 2013;5(193):193ra191. CrossRef
Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV, Wanke CA, Ward HD. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. Asian J Infect Dis. 2015;211(1):19–27. CrossRef
Lever M, George PM, Slow S, Bellamy D, Young JM, Ho M, McEntyre CJ, Elmslie JL, Atkinson W, Molyneux SL, et al. Betaine and Trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study. PLoS One. 2014;9(12):e114969. CrossRefPubMedPubMedCentral
Troseid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, Aakhus S, Gude E, Bjorndal B, Halvorsen B, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med. 2015;277(6):717–26. CrossRefPubMed
Pedersen KK, Manner IW, Selje I, Kvale D, Os I, Gerstoft J, Nielsen SD, Trøseid M. Monocyte activation, but not microbial translocation, is independently associated with markers of endovascular dysfunction in HIV-infected patients receiving cART. J Acquir Immune Defic Syndr. 2014;67(4):370–4. CrossRefPubMed
Centre of Excellence for Health, Immunity and Infectious Diseases. [ http://chip.dk/Tools].
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality an individual partticipant meta-analysis. Lancet. 375(9709):132–40.
Borges AH, O'Connor JL, Phillips AN, Ronsholt FF, Pett S, Vjecha MJ, French MA, Lundgren JD. Factors associated with plasma IL-6 levels during HIV infection. Asian J Infect Dis. 2015;212(4):585–95. CrossRef
McEvoy JW, Nasir K, DeFilippis AP, Lima JA, Bluemke DA, Hundley WG, Barr RG, Budoff MJ, Szklo M, Navas-Acien A, et al. Relationship of cigarette smoking with inflammation and subclinical vascular disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35(4):1002–10. CrossRefPubMedPubMedCentral
Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obesity Rev. 2013;14(3):232–44. CrossRef
Haissman JM, Knudsen A, Hoel H, Kj AA, Kristoffersen US, Berge RK, Katzenstein TL, Svardal A, Ueland T, Aukrust P et al.: Microbiota-dependent marker TMAO is elevated in silent ischemia but is not associated with first-time myocardial infarction in HIV infection. J Acquir Immune Defic Syndr 2015.
- HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation
Julie Christine Gaardbo
Rolf Kristian Berge
Susanne Dam Nielsen
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II